BioSpace News Archive

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes.

Dyne Therapeutics, Inc.today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences.

AnPac Bio-Medical Science Co., Ltd. announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio’s Model AP9080 cancer detection devices.

Neuronetics, Inc. today announced its financial and operating results for the fourth quarter and full year of 2022.

POINT Biopharma Global Inc. today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.

Arch Therapeutics, Inc. today announced an expansion of its contracted sales force with a dedicated team of independent representatives whose primary objective will be to support surgeons and other medical professionals as well as advance the commercialization of AC5 ® Advanced Wound System.

Calyx today announced the availability of Calyx Supply Simulation, a clinical trial supply forecasting service available through Calyx’s in-house expert statistical design and trial supplies consultants.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the virtual Oppenheimer 33rd Annual Healthcare Conference.

Solid Biosciences Inc. announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 3:35 PM ET.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023.